Abstract
Androgen withdrawal or surgical castration remains the standard therapy for advanced prostate cancer disease. Even for castration-resistant prostate cancer the therapeutic option of docetaxel-based chemotherapy is well studied and defined. Facing disease progression after docetaxel-based therapy there are multiple options to continue therapy but the evidence level is rather poor. In the last few years targeted therapy and immunomodulation have been the focus of clinical trials. The presented manuscript intends to provide an overview of classical cytostatic agents, endothelin inhibitors, immunotherapy, modified hormone therapy, multikinase inhibitors and radionuclide approaches which are currently under investigation for implementation in the clinical setting.
MeSH terms
-
Androgen Antagonists / administration & dosage*
-
Androgen Antagonists / adverse effects
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Docetaxel
-
Drug Resistance, Neoplasm
-
Endothelin Receptor Antagonists
-
Epothilones / administration & dosage
-
Epothilones / adverse effects
-
Evidence-Based Medicine
-
Humans
-
Immunotherapy / methods
-
Male
-
Neoplasm Staging
-
Orchiectomy*
-
Palliative Care / methods*
-
Practice Guidelines as Topic
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Prostatic Neoplasms / mortality
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / therapy*
-
Randomized Controlled Trials as Topic
-
Survival Rate
-
Taxoids / administration & dosage
-
Taxoids / adverse effects
-
Tubulin Modulators / administration & dosage
-
Tubulin Modulators / adverse effects
Substances
-
Androgen Antagonists
-
Antineoplastic Agents
-
Endothelin Receptor Antagonists
-
Epothilones
-
Taxoids
-
Tubulin Modulators
-
Docetaxel
-
Prednisone